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background: Non-steroidal anti-inﬂammatory drug (NSAID)-activated gene-1 (NAG-1) is involved in cellular processes such as
inﬂammation, apoptosis and tumorigenesis. However, little is known about the expression and function of NAG-1 in the endometrium.
This study aimed to evaluate the expression of NAG-1 in the endometrium and in the absence or presence of endometriosis and to inves-
tigate the effect of celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, on NAG-1 mRNA levels and apoptosis in human endometrial
stromal cells (HESCs).
methods: Eutopic endometrial samples were obtained during surgery from 40 patients with, and 40 patients without, endometriosis.
Real-time PCR was used to quantify NAG-1 mRNA levels and immunohistochemistry was used to localize NAG-1 protein in the endome-
trium. To investigate the effects of celecoxib, HESCs were isolated and cultured with different concentrations of celecoxib or with 100 mM
celecoxib at different times. Apoptosis was assessed by ﬂow cytometry.
results: NAG-1 mRNA levels and immunoreactivity showed cyclical changes through the menstrual cycle, increasing during the late
secretory and menstrual phases. NAG-1 mRNA and protein levels were signiﬁcantly lower in patients with endometriosis, compared
with the control group. Celecoxib induced NAG-1 mRNA levels and apoptosis in cultured HESCs, with the effects dependent on drug con-
centrations and duration of treatment. Celecoxib treatment had no effect on prostaglandin E2 levels in the culture supernatants.
conclusions: NAG-1 may be important in maintaining homeostasis in the normal endometrium and alterations in NAG-1 expression
may be associated with the establishment of endometriosis. NAG-1 might be a therapeutic target for endometriosis.
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Introduction
The human endometrium is a dynamic tissue that undergoes monthly
cyclic changes, including proliferation, differentiation and degeneration.
These sequential changes are regulated by ovarian steroid hormones
and apoptosis appears to play an important role in cyclic remodeling
of the endometrium (Hopwood and Levison, 1976; Kokawa et al.,
1996). Evidence suggests that apoptosis mainly occurs in the human
endometrium through the late secretory to menstrual phases and
the BCL-2 family and Fas/FasL system are involved in the regulation
of apoptosis (Kokawa et al., 1996; Harada et al., 2004).
Endometriosis, which is the presence of endometrial glands and
stroma at extrauterine locations, is a benign gynecological disease
that may cause infertility and pelvic pain. It is a common disease
that affects about 10% of reproductive-age women and 20–50% of
infertile women (Eskenazi and Warner, 1997; Pritts and Taylor,
2003). Various theories have been proposed about the pathogenesis
of endometriosis, but a deﬁnitive theory remains obscure. The most
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widely accepted theory presumes that endometriosis is caused by
implantation and growth of reﬂuxed endometrial cells into the perito-
neal cavity, and several studies have asserted that reduced apoptosis
could contribute to the survival of reﬂuxed endometrial cells and
the establishment of endometriosis (Gebel et al., 1998; Dmowski
et al., 2001).
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are clinically used
as therapeutic agents for pain and inﬂammation. Recently, the use of
NSAIDs was extended to chemoprevention of colorectal cancer
(Cuzick et al., 2009). Experimental evidence suggests that NSAIDs
exert their chemopreventive effects by induction of apoptosis, cell
growth suppression, inhibition of angiogenesis and inhibition of metas-
tasis (Gupta and Dubois, 2001; Kismet et al., 2004). Previously, inhi-
bition of cyclooxygenase (COX)-1 and/or COX-2 activity by
NSAIDs was thought to be the sole explanation for their chemopre-
ventive effect. However, COX-independent effects may contribute
to their anti-cancer activity (Hanif et al., 1996; Piazza et al., 1997;
Minter et al., 2003; Pang et al., 2007). More recently, a selective
COX-2 inhibitor was found to enhance apoptosis in human endo-
metrial epithelial cells (HEECs) in women with and without endome-
triosis (Olivares et al., 2008). However, little is known about the genes
involved in the intracellular regulatory events that determine the sus-
ceptibility of endometrial cells to NSAID-induced apoptosis.
Non-steroidal anti-inﬂammatory drug-activated gene-1 (NAG-1) is
a member of the transforming growth factor (TGF)-b superfamily,
which is associated with cell growth, differentiation and apoptosis
(Li et al., 2000; Baek et al., 2001). NAG-1 is activated by various
NSAIDs, including selective COX-2 inhibitors, but its precise biologi-
cal functions are not fully understood. Previous studies demonstrated
that NAG-1 had pro-apoptotic and anti-tumorigenic activities. The
over-expression of NAG-1 by COX-2 inhibitors in various cancer
cells results in apoptosis induction and growth arrest (Baek et al.,
2004; Kim et al., 2005; Kim et al., 2008; Yoshioka et al., 2008).
Thus, NAG-1 seems to be a link between NSAIDs and their
pro-apoptotic activity and might explain NSAID-induced apoptosis.
However, the expression of NAG-1 in the endometrium and its
relationship to endometriosis has not been reported.
Therefore, we evaluated NAG-1 expression in the endometrium
and investigated whether altered NAG-1 expression is associated
with endometriosis. In addition, we assessed the effect of celecoxib,
a selective COX-2 inhibitor, on NAG-1 mRNA levels and apoptosis
in human endometrial cells.
Materials and Methods
Participants
Patients of reproductive age who were treated for benign gynecological
conditions at Gangnam Severance Hospital in Seoul, Korea participated
in this study. All patients had regular menstrual cycles (range: 26–
32 days) and had not undertaken hormonal therapy with agents such as
GnRH agonsists or steriods, for at least 6 months before endometrial
sampling. Patients with gynecological cancer or endometrial pathologies,
such as endometrial hyperplasia or endometrial polyps, were excluded.
Eutopic endometrial samples were obtained from 40 patients with
endometriosis (mean age: 32.6 years; range: 22–45 years) and 40 patients
without endometriosis (mean age: 34.6 years; range: 21–47 years) by
endometrial curettage before surgical procedures. All 40 patients with
endometriosis were at revised American Society for Reproductive Medi-
cine (ASRM) stage III (n ¼ 24) or revised ASRM stage IV (n ¼ 16), as diag-
nosed by histological examination of the ectopic endometrial specimens
taken at the time of laparoscopy. The control group included 21 patients
with benign ovarian cysts, 6 patients with ﬁbroids, 11 patients with cervical
intraepithelial neoplasia and 2 patients without visible pathology in the
pelvis. Benign ovarian cysts included functional cysts, simple cysts, paratu-
bal cysts and dermoid cysts.
Endometrial dating was determined by menstrual history and endo-
metrial histological features (Noyes et al., 1950) and divided into early pro-
liferative, late proliferative, early secretory, mid-secretory, late secretory
and menstrual phases. The 40 endometriosis patients were distributed
as menstrual (n ¼ 8), early proliferative (n ¼ 8), late proliferative (n ¼
8), early secretory (n ¼ 6), mid-secretory (n ¼ 5) and late secretory
(n ¼ 5), and the 40 control women were distributed as menstrual (n ¼
8), early proliferative (n ¼ 8), late proliferative (n ¼ 8), early secretory
(n ¼ 5), mid-secretory (n ¼ 5) and late secretory (n ¼ 6).
This study was approved by the Institutional Review Board of Gangnam
Severance Hospital and written informed consent was obtained from
participants.
RNA extraction and SYBR green real-time
PCR
Total RNA was extracted from endometrial tissue using the RNeasy Mini
Kit (Qiagen, Valencia, CA, USA) and 2 mg was reverse transcribed into
cDNA by SuperScript III ﬁrst-strand synthesis system (Invitrogen, Carls-
bad, CA, USA), according to the manufacturer’s instructions. NAG-1
mRNA levels were measured by SYBR green real-time PCR using an
ABI PRISM 7300 sequence detection system (Applied Biosystems, Foster
City, CA, USA). b-actin, a housekeeping gene, was used as a normalization
control. Speciﬁc primers for NAG-1 (Hs 00171132) and b-actin (Hs
99999903) were obtained from Applied Biosystems. PCR ampliﬁcation
was performed in 20 mL with 2 mL of cDNA, 5 rM of each primer, and
power SYBR green PCR master mix (Applied Biosystems). Thermal
cycling conditions were 2 min at 508C, 10 min at 958C, followed by 40
cycles of 15 s at 958C and 1 min at 608C. Relative NAG-1 mRNA levels
were calculated by the DDCt method using the normalization formula
(Livak and Schmittgen, 2001): target amount ¼ 22DDCt, where DDCt ¼
[Ct (NAG-1 sample) – Ct (b-actin sample)] – [Ct (NAG-1 calibrator)
– Ct (b-actin calibrator)].
Immunohistochemistry
The Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA) was
used for immunohistochemistry (IHC). Parafﬁn embedded sections were
deparafﬁnized with xylene, rehydrated in a graded ethanol series and
immersed in 3% H2O2 for 10 min to block endogenous peroxidase. Sec-
tions were incubated with the anti-NAG-1 rabbit polyclonal IgG (1:200
dilution; Upstate, Lake Placid, NY, USA) overnight at 48C, rinsed with a
washing buffer, and incubated with biotinylated second antibody (rabbit
IgG) solution for 30 min at room temperature. After 5-min washes in
buffer, Vecstatin ABC Reagent was applied for 30 min. Chromogen sol-
ution was added for 2 min and slides were counterstained with Meyer’s
hematoxylin. Negative controls used a secondary antibody without the
primary antibody.
For H-scores, ﬁve randomly selected areas were evaluated under a light
microscope at 400× magniﬁcation. NAG-1 intensity was evaluated as: 0
(no staining), 1+ (weak staining), 2+ (moderate staining) and 3+
(strong staining). For each slide, an H-score was calculated as follows:
H-score ¼ (% of cells that stained at intensity category 1 × 1) + (% of
cells that stained at intensity category 2 × 2) + (% of cells that stained
at intensity category 3 × 3). Slides were scored at different times by
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two investigators blinded to the clinical data. The average of the two evalu-
ations was used for the ﬁnal analysis.
Isolation and culture of endometrial stromal
cells
Human endometrial stromal cells (HESCs) were isolated from endometrial
tissue of 15 patients with ﬁbroids undergoing hysterectomy and cultured as
described previously (Lee and Nowak, 2001; Park et al., 2003). Brieﬂy,
endometrial tissues were minced into small pieces and placed in
Dulbecco’s modiﬁed Eagle’s medium (DMEM)/F12 (Gibco-BRL, Gaithers-
burg, MD, USA) supplemented with 10% fetal bovine serum (FBS;
Gibco-BRL) with 5 ml of 0.25% trypsin-ethylenediaminetetraacetic acid
(EDTA) solution (Gibco-BRL). Endometrial tissue was digested for
30 min in a 378C incubator with gentle shaking. Dispersed cells were cen-
trifuged at 2000 g for 5 min and the cell pellet was re-suspended in
DMEM/F12 plus 10% FBS. The stromal-enriched fraction was cultured
in 75-ml culture ﬂasks at 378C in a humidiﬁed atmosphere of 95% air
and 5% CO2. We used HESCs in a monolayer culture after the ﬁrst
passage. The purity of the HESCs was assessed by IHC for vimentin and
cytokeratin. The IHC results demonstrated that the purity of HESCs
was .95%.
Effect of celecoxib on NAG-1 mRNA levels
and prostaglandin E2 production in cultured
HESCs
HESCs were plated at 1 × 105 cells per well in six-well plates for real-time
PCR. After 48 h in 10% FBS medium, HESCs were washed and cultured
with 0% FBS medium and treated with celecoxib at 0, 25, 50 or
100 mM for 24 h or with 100 mM celecoxib for 0, 12, 24 or 48 h. The
total RNA was extracted from cultured HESCs using the RNeasy Mini
Kit (Qiagen) and NAG-1 mRNA levels were measured as described
above.
The culture supernatants were collected for measuring levels of prosta-
glandin E2 (PGE2) using an ELISA kit (Cusabio Biotech, China), according
to the manufacturer’s protocols. The minimum detectable concentration
was 20 pg/ml.
Measurement of apoptototic HESCs by ﬂow
cytometry
1 × 106 HESCs per well were plated in 10-cm culture dishes. After 48 h in
10% FBS medium, HESCs were washed and cultured with 0% FBS medium,
and treated with celecoxib at the concentrations and times described
above before collection for the apoptosis assay. HESCs were stained
with propidium iodide, according to the manufacturer’s protocol. Apopto-
tic cells were assessed by ﬂow cytometry (FC 500, Beckman Coulter, Full-
erton, CA, USA) and data were analyzed using WinMDI version 2.9
software (The Scripps Research Institute, San Diego, CA, USA).
Statistical analysis
Data were expressed as the mean+ SEM. The Mann–Whitney U-test was
used to compare the NAG-1 mRNA levels and H-scores between the two
groups. Differences in the NAG-1 mRNA levels and H-scores over the
menstrual cycle within each group were compared using the Kruskal–
Wallis test followed by Dunn’s procedure. NAG-1 mRNA levels and
apoptotic index after different COX-2 inhibitor treatment concentrations
and times were compared with the control using the Mann–Whitney
U-test. All statistical analyses were performed using SPSS version 15.0 soft-
ware (SPSS, Inc., Chicago, IL, USA). A P-value of ,0.05 was considered
statistically signiﬁcant.
Results
NAG-1 endometrial mRNA levels
NAG-1 mRNA levels showed cyclical changes through the menstrual
cycle and signiﬁcantly increased during the late secretory and men-
strual phases in both endometriosis patients and controls. However,
the variability of NAG-1 mRNA levels appeared to be lower in the
endometriosis group. When the NAG-1 mRNA levels were com-
pared by menstrual cycle, NAG-1 mRNA levels were signiﬁcantly
lower during the late secretory and menstrual phases in the endome-
triosis group than in the control group (Fig. 1).
Immunohistochemistry
NAG-1 was expressed in glandular epithelial and stromal cells
throughout the menstrual cycle, localized within the cytoplasm.
NAG-1 immunostaining varied over the menstrual cycle in both
groups. In the proliferative, early secretory and mid-secretory
phases, NAG-1 staining in glandular epithelial cells was weak, and
stromal cells were negative or very weakly stained. Although the
immunoreactivity of NAG-1 increased during the late secretory and
menstrual phases in both groups, NAG-1 expression was signiﬁcantly
lower in both glandular epithelial cells and stromal cells of the endo-
metriosis group, when compared with the control group (Fig. 2).
Induction of NAG-1 mRNA levels and
apoptosis by celecoxib in cultured HESCs
Treatment with celecoxib signiﬁcantly increased both NAG-1 mRNA
levels and HESC apoptosis, and both of these effects depended on cel-
ecoxib concentration (Fig. 3). In addition, NAG-1 mRNA levels and
apoptosis also increased with the duration of treatment with
100 mM celecoxib (Fig. 4).
Figure 1 Comparison of NAG-1 mRNA levels in endometriosis
and control group through the menstrual cycle. M, menstrual
phase; EP, early proliferative phase; LP, late-proliferative phase; ES,
early secretory phase; MS, mid-secretory phase; LS, late-secretory
phase. Data are expressed as mean+ SEM. aStatistically signiﬁcant
versus LP, ES and MS in the Dunn procedure. bStatistically signiﬁcant
versus LP and ES in the Dunn procedure.
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Effect of celecoxib on PGE2 production
We investigated COX-2 activity by measuring levels of PGE2 released
into the conditioned media of cultured HESCs treated for 24 h with
different concentrations of celecoxib. In HESCs treated with celecoxib
up to 100 mM, no signiﬁcant reduction of PGE2 levels was observed
(Fig. 5).
Discussion
We found cyclic expression of NAG-1 in the human endometrium
over the menstrual cycle and demonstrated altered NAG-1
expression in the eutopic endometrium from women with endome-
triosis. We also found that celecoxib increased NAG-1 mRNA
levels and apoptosis in cultured HESCs.
TGF-b superfamily members are stage-speciﬁcally expressed in the
human endometrium, consistent with their general role in tissue
homeostasis (Jones et al., 2006). NAG-1, a member of the TGF-b
superfamily, was cyclically expressed in endometrial epithelial and
stromal cells, peaking during the late secretory and menstrual
phases. When comparing patients with endometriosis with a control
group, NAG-1 expression was signiﬁcantly decreased in both endo-
metrial glandular and stroma cells of patients with endometriosis
during the late secretory and menstrual phases. The cyclic variability
of NAG-1 expression was also reduced in the endometriosis group.
The present study further demonstrated that NAG-1 was associated
with apoptosis in cultured HESCs. Previous studies have shown that
in patients with endometriosis, the number of apoptotic cells is signiﬁ-
cantly lower during the late secretory and menstrual phases in both
endometrial glandular and stroma cells and apoptotic cyclic variability
is not seen (Johnson et al., 2005; Szymanowski, 2007). Both endo-
metrial glandular and stroma cells have a higher proliferative capacity
in women with endometriosis, when compared with normal controls
(Wingﬁeld et al., 1995; Johnson et al., 2005). Moreover, aberrant
expression of apoptosis-related molecules in patients with endome-
triosis may account for the individual susceptibility to endometriosis
(Harada et al., 2004). Therefore, altered expression of NAG-1 may
affect apoptosis of endometrial cells and be involved in the pathogen-
esis of endometriosis.
In the animal model, celecoxib prevents the implantation of endo-
metrial tissue and induces the regression of endometrial implants at
ectopic sites by suppressing angiogenesis and inducing apoptosis
Figure 2 Expression of NAG-1 in the endometrium (×400). Representative micrographs of NAG-1 immunostaining in the endometrium of the
control (A) and endometriosis group (B), and H-score in endometrial glandular (C) and stromal cells (D) throughout the menstrual cycle. M, men-
strual phase; EP, early proliferative phase; LP, late-proliferative phase; ES, early secretory phase; MS, mid-secretory phase; LS, late-secretory phase.
Data are expressed as mean+ SEM. aStatistically signiﬁcant versus EP, LP, and ES in the Dunn procedure. bStatistically signiﬁcant versus EP and LP in
the Dunn procedure. cStatistically signiﬁcant versus LP in the Dunn procedure.
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(Matsuzaki et al., 2004). Recently, celecoxib was found to inhibit pro-
liferation and induce apoptosis of HEECs. Treatment with ≥50 mM
celecoxib showed a signiﬁcant effect on endometrial growth and
enhanced apoptosis in cultured HEECs compared with controls
(Olivares et al., 2008). Our study also found that ≥50 mM celecoxib
signiﬁcantly increased apoptosis in cultured HESCs. These results
Figure 3 Dose-dependent NAG-1 expression (A) and apoptosis (B) in cultured HESCs. HESCs were treated with celecoxib as indicated for 24 h.
Apoptotic HESCs were assessed by ﬂow cytometry (C). Data are expressed as mean+ SEM of ﬁve independent experiments. aP, 0.05 versus 0 mM,
bP, 0.05 versus 25 mM, cP, 0.05 versus 50 mM.
Figure 4 Time-dependent NAG-1 expression (A) and apoptosis (B) in cultured HESCs. HESCs were treated with 100 mM celecoxib as indicated.
Apoptotic HESCs were assessed by ﬂow cytometry (C). Data are expressed as mean+ SEM of ﬁve independent experiments. aP, 0.01 versus 0 and
12 h.
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suggest that selective COX-2 inhibitors may be effective for the pre-
vention and treatment of endometriosis. Selective COX-2 inhibitors
also provide pain relief with fewer gastrointestinal side effects than
non-selective COX inhibitors. However, selective COX-2 inhibitors
may increase the risk of cardiovascular thrombotic disease (Mukherjee
et al., 2001).
It is generally accepted that COX-2 inhibitors induce apoptosis
through inhibition of COX-2 expression and subsequent PGE2 pro-
duction. However, accumulating evidence suggests that COX-
independent pathways may be involved in the effects of COX-2 inhibi-
tors. Signiﬁcantly higher concentrations of NSAIDs are necessary to
inhibit cell growth and to induce apoptosis than those required for
the inhibition of PGE2 production (Hanif et al., 1996; Piazza et al.,
1997; Minter et al., 2003) and exogenous addition of PGE2 cannot
reverse the apoptosis-inducing effects of NSAIDs (Hanif et al., 1996;
Piazza et al., 1997). Furthermore, NSAIDs induce apoptosis in
COX-2-deﬁcient cell lines (Elder et al., 1997; Pang et al., 2007).
This study showed that celecoxib treatment had no effect on PGE2
levels in culture supernatants, whereas ≥50 mM celecoxib signiﬁcantly
increased NAG-1 mRNA levels and apoptosis in cultured HESCs.
These results strongly support the hypothesis that celecoxib-induced
apoptosis in endometrial stromal cells is independent of COX-2.
NAG-1 is a pro-apoptotic and anti-tumorigenic gene induced by
various NSAIDs, and its expression is lower in colon and prostate
cancers compared with adjacent normal tissue (Thomas et al., 2001;
Kim et al., 2002). In addition, overexpression of NAG-1 by NSAIDs
results in growth arrest and increases apoptosis in various cancer
cells (Baek et al., 2004; Kim et al., 2005; Kim et al., 2008; Yoshioka
et al., 2008). Here, we demonstrated that NAG-1 mRNA levels are
up-regulated by celecoxib and that increased NAG-1 mRNA levels
are associated with apoptosis induction. We also demonstrated that
celecoxib increases NAG-1 mRNA levels and apoptosis in a dose-
and time-dependent manner. Consequently, the effects of COX-2
inhibitors on apoptosis in endometrial cells may be mediated, at
least in part, by NAG-1, and NAG-1 may be a potential target for
the prevention and treatment of endometriosis as well as for
various cancers.
To our knowledge, this is the ﬁrst report to examine NAG-1
expression in the human endometrium. Furthermore, we are also
the ﬁrst to report alterations in NAG-1 expression in women with
endometriosis and provide a partial explanation for a novel signaling
pathway to induce apoptosis of endometrial cells by COX-2 inhibitors.
In conclusion, we reported cyclic changes in NAG-1 expression in
the human endometrium through the menstrual cycle and showed a
signiﬁcant decrease in NAG-1 expression in patients with endometrio-
sis compared with controls during the late secretory and menstrual
phases. We also demonstrated that a COX-2 inhibitor increased
NAG-1 mRNA levels and apoptosis in human endometrial cells.
These results suggest that NAG-1 plays an important role in maintain-
ing homeostasis of the normal endometrium by regulating apoptosis,
and that changes in NAG-1 expression may contribute to the estab-
lishment of endometriosis. Therefore, NAG-1 can be a therapeutic
target for endometriosis.
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